165 reports of this reaction
1.7% of all TASIMELTEON reports
#13 most reported adverse reaction
INCORRECT PRODUCT ADMINISTRATION DURATION is the #13 most commonly reported adverse reaction for TASIMELTEON, manufactured by Vanda Pharmaceuticals Inc.. There are 165 FDA adverse event reports linking TASIMELTEON to INCORRECT PRODUCT ADMINISTRATION DURATION. This represents approximately 1.7% of all 9,924 adverse event reports for this drug.
Patients taking TASIMELTEON who experience incorrect product administration duration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INCORRECT PRODUCT ADMINISTRATION DURATION is a less commonly reported adverse event for TASIMELTEON, but still significant enough to appear in the safety profile.
In addition to incorrect product administration duration, the following adverse reactions have been reported for TASIMELTEON:
The following drugs have also been linked to incorrect product administration duration in FDA adverse event reports:
INCORRECT PRODUCT ADMINISTRATION DURATION has been reported as an adverse event in 165 FDA reports for TASIMELTEON. This does not prove causation, but indicates an association observed in post-market surveillance data.
INCORRECT PRODUCT ADMINISTRATION DURATION accounts for approximately 1.7% of all adverse event reports for TASIMELTEON, making it a notable side effect.
If you experience incorrect product administration duration while taking TASIMELTEON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.